Epstein Secrets

n peer-reviewed journals, including Neuron, Science and Nature. Eric Kim, (28), Associate, joined New Leaf in December 2013. From 2011 through 2013, Eric was a Private Equity Associate at Francisco Partners, where he focused on diligence and company oversight efforts on the firm’s healthcare informatio

t and XDx, while maintaining board observer status with Labcyte. Vijay was previously on the boards of Advanced Cell Diagnostics, Ilypsa (acquired by Amgen) and Relypsa (NASDAQ: RLYP). Prior to joining Sprout, Vijay spent one year as an analyst in the healthcare venture capital group at Robertson Stephen

quently split to become 2 separate companies), Durata Therapeutics (NLV-II: IPO - July, 2012, NASDAQ: DRTX), and Ilypsa (Sprout IX, exited in sale to Amgen, 6.9x multiple). e Established Private Companies: The New Leaf Team has played the role of lead investor in a large number of private investments. T

astern District of Virginia "decided Tuesday that Eric B. Brown was not competent to stand trial in the

ing on `unsustainable drug prices' concludes — Hybrid hearing on `Unsustainable Drug Prices: Testimony from the CEOs (Part II)', with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM * Tom Lantos Human

stern District of Virginia "decided Tuesday that Eric B. Brown was not competent to stand trial in the

ing on 'unsustainable drug prices' concludes - Hybrid hearing on 'Unsustainable Drug Prices: Testimony from the CEOs (Part II)', with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM • Tom Lantos Human

stern District of Virginia "decided Tuesday that Eric B. Brown was not competent to stand trial in the

ring on `unsustainable drug prices' concludes - Hybrid hearing on Unsustainable Drug Prices: Testimony from the CEOs (Part II); with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM • Tom Lantos Human

ric Autopsy Project (mass murder and suicides by Eric Harris and Dylan Klebold at Columbine High Schoo

Strauss, San Francisco, CA, September 9, 1998 American Express, Newark, NJ, October 20-21, 1998 Eastman Kodak, Rochester, NY, November 17-18, 1998 Amgen, Thousand Oaks, CA, December 1-3, 1998 Darden Restaurant Group, Orlando, FL, December 14-15, 1998 3M Company, St. Paul, MN, December 16, 1998 Media

stern District of Virginia "decided Tuesday that Eric B. Brown was not competent to stand trial in the

ng on 'unsustainable drug prices' concludes - Hybrid hearing on 'Unsustainable Drug Prices: Testimony from the CEOs (Part II)', with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM • Tom Lantos Human